AstraZeneca (AZN) Shares Down 0.5%
AstraZeneca PLC (LON:AZN)’s share price dropped 0.5% on Monday . The company traded as low as GBX 4,734.50 ($63.72) and last traded at GBX 4,745 ($63.86). Approximately 1,823,066 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 2,180,000 shares. The stock had previously closed at GBX 4,767 ($64.16).
A number of brokerages have commented on AZN. Liberum Capital restated a “buy” rating and set a GBX 4,800 ($64.60) price objective on shares of AstraZeneca in a research report on Tuesday, September 5th. raised their price objective on AstraZeneca from GBX 4,100 ($55.18) to GBX 4,150 ($55.85) and gave the stock a “reduce” rating in a research report on Monday, October 9th. UBS set a GBX 4,550 ($61.24) price objective on AstraZeneca and gave the stock a “neutral” rating in a research report on Monday, October 23rd. Jefferies Group raised their price objective on AstraZeneca from GBX 4,350 ($58.55) to GBX 4,800 ($64.60) and gave the stock a “hold” rating in a research report on Monday, September 11th. Finally, Deutsche Bank restated a “buy” rating and set a GBX 5,600 ($75.37) price objective on shares of AstraZeneca in a research report on Wednesday, October 11th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of GBX 5,169 ($69.57).
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related stocks with our FREE daily email newsletter.